Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Immutep Limited American Depositary Shares (IMMP)

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/01/1988

Market Cap

287,995,920

Shares Outstanding

1,188,840,000

Weighted SO

118,883,456

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

CWBR --.--%

OCEA --.--%

ELEV --.--%

AVRO --.--%

ZURA --.--%

CNSP --.--%

ZVSA --.--%

EFTR --.--%

Beta

1.9160

Last Div

0.0000

Range

1.58-3.34

Chg

0.1100

Avg Vol

379919

Mkt Cap

287995920

Exch

NASDAQ

Country

AU

Phone

61 2 8315 7003

DCF Diff

2.2230

DCF

0.0470

Div Yield

0.0000

P/S

109.8411

EV Multiple

-7.3015

P/FV

35.3788

Div Yield %

0.0000

P/E

-101.0165

PEG

-7.0520

Payout

0.0000

Current Ratio

17.2399

Quick Ratio

17.2399

Cash Ratio

15.8212

DSO

570.7619

DIO

0.0002

Op Cycle

570.7621

DPO

576.7793

CCC

-6.0171

Gross Margin

0.5116

Op Margin

-11.9740

Pretax Margin

-10.3032

Net Margin

-10.3032

Eff Tax Rate

0.0000

ROA

-0.3272

ROE

-0.3213

ROCE

-0.4015

NI/EBT

1.0000

EBT/EBIT

0.8605

EBIT/Rev

-11.9740

Debt Ratio

0.0090

D/E

0.0096

LT Debt/Cap

0.0077

Total Debt/Cap

0.0095

Int Coverage

-2905.4988

CF/Debt

-24.0884

Equity Multi

1.0704

Rec Turnover

0.6395

Pay Turnover

0.6328

Inv Turnover

999999.9999

FA Turnover

4.9418

Asset Turnover

0.0318

OCF/Share

-0.0223

FCF/Share

-0.0230

Cash/Share

0.0867

OCF/Sales

-6.7900

FCF/OCF

1.0332

CF Coverage

-24.0884

ST Coverage

-127.0280

CapEx Coverage

-30.1253

Div&CapEx Cov

-30.1253

P/BV

35.3788

P/B

35.3788

P/S

109.8411

P/E

-101.0165

P/FCF

-15.6572

P/OCF

-153.2838

P/CF

-153.2838

PEG

-7.0520

P/S

109.8411

EV Multiple

-7.3015

P/FV

35.3788

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Jul 22, 02:47 Guess which ASX healthcare stock is surging on big FDA news - The Motley Fool Australia The Motley Fool Jul 22, 02:16 Why 29Metals, Immutep, Insignia, and Perenti shares are pushing higher today - The Motley Fool Australia GlobeNewswire Inc. Jun 03, 00:38 Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Revenue Product Segmentation